Related Experiment Video

Updated: May 19, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Safety and efficacy of an ultrashort-acting β1-blocker on left ventricular dysfunction

Nobuhisa Ito1, Tadashi Tashiro, Noritsugu Morishige

  • 1Department of Cardiovascular Surgery, Fukuoka University School of Medicine, Fukuoka, Japan. noby.ito@nifty.ne.jp

The Heart Surgery Forum
|August 25, 2012
PubMed

Insights

Landiolol hydrochloride effectively reduced postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting (CABG) with left ventricular dysfunction. This ultrashort-acting beta-blocker maintained hemodynamic stability without increasing other complications.

Area of Science:

  • Cardiac Surgery
  • Pharmacology
  • Critical Care Medicine

Background:

  • Landiolol hydrochloride is an ultrashort-acting, beta1-selective blocker.
  • Left ventricular dysfunction is a critical factor in patients undergoing coronary artery bypass grafting (CABG).

Purpose of the Study:

  • To evaluate the safety and efficacy of landiolol hydrochloride in patients with left ventricular dysfunction undergoing CABG.
  • To assess the impact of landiolol hydrochloride on postoperative atrial fibrillation and hemodynamic stability.

Main Methods:

  • A comparative study involving 32 patients with left ventricular ejection fraction <40% undergoing CABG between September 2006 and August 2009.
  • Patients were divided into a landiolol hydrochloride administration group and a control group.
  • Landiolol hydrochloride was administered at 1 μg/kg/min post-cardiopulmonary bypass (on-pump) or post-distal anastomoses (off-pump).

Main Results:

  • No significant differences in preoperative patient background or overall complication rates were observed between groups.
  • A significant decrease in heart rate was noted 30 minutes post-administration, with stable arterial pressure and hemodynamics.
  • The incidence of postoperative atrial fibrillation was significantly lower in the landiolol hydrochloride group.

Conclusions:

  • Landiolol hydrochloride administration was associated with a significant reduction in postoperative atrial fibrillation in CABG patients with left ventricular dysfunction.
  • Landiolol hydrochloride demonstrated a sole inhibitory effect on atrial fibrillation, indicating its potential as a protective agent in this patient population.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...